[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidin-1-ium-1-ylpiperidine-4-carbonyl]azanium;dichloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidin-1-ium-1-ylpiperidine-4-carbonyl]azanium;dichloride
• 化学式: C21H32Cl2FN3O2
• 分子量: 448.4
• InChiKey: BMXXSXQVMCXGJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.23
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  69
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Medical Use of Compound III
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180237445A1

  公开（公告）日：2018-08-23

  The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.

  本发明涉及化合物III及其用于治疗和/或预防精神分裂症谱系和其他精神疾病的疾病，这些疾病的首次发作，如精神病的首次发作（FEP），这些疾病的复发，如减少精神分裂症患者复发（REX）。本发明还涉及化合物III的多晶形式，以及包含化合物III和/或其多晶形式的制药组合物。
• CRYSTALLINE CONDITION DISLOCATING METHOD
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0665009A1

  公开（公告）日：1995-08-02

  An object of this invention is to provide a method of dislocating the crystalline condition of crystalline medicine simply, speedily and homogeneously, and, moreover, in large quantities at once. This invention is directed to a method using an extruder when crystalline medicine in a certain crystalline condition (△ is dislocated to another crystalline condition (○), i.e., when the dislocation of crystalline condition (△->○) is carried out.

  本发明的目的是提供一种简单、快速和均匀地将结晶药物的结晶状态变位的方法，而且是一次性大量变位。本发明针对的是一种使用挤压机将某种结晶状态（△）的结晶药物变位到另一种结晶状态（○）的方法，即结晶状态（△->○）变位的方法。
• Pharmaceutical preparations based on active ingredients susceptible to illict administration
  申请人：ALTERGON S.A.

  公开号：EP1273301A2

  公开（公告）日：2003-01-08

  The present invention provides oral pharmaceutical preparations unsuitable for illicit administration to victims.

  本发明提供了不适合非法给受害者服用的口服药物制剂。
• Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
  申请人：B&B Beheer NV

  公开号：EP1541197A1

  公开（公告）日：2005-06-15

  The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability - hypersensitivity - hyperaesthesia - dissociative phenomena - etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

  本发明涉及具有D4和5-HT2A拮抗、部分激动或反向激动活性的化合物和化合物组合物用于治疗精神障碍（即情感不稳定性-超敏性-超感觉-分离现象等）的潜在情感功能失调。本发明还涉及以下方法：向被诊断为患有神经精神障碍的患者施用药物组合物，该药物组合物含有(i) 具有D4拮抗、部分激动或反向激动活性的化合物和(ii) 具有5-HT2A拮抗、部分激动或反向激动活性的化合物，以及(iii) 任何已知的药用化合物和所述化合物的组合物。D4和5-HT2A拮抗、部分激动或反向激动的组合效应可以存在于相同的化学或生物化合物中，也可以存在于两种不同的化学和/或生物化合物中。
• Low dose pipamperone in treating mood and anxiety disorders
  申请人：PharmaNeuroBoost N.V.

  公开号：EP2236138A1

  公开（公告）日：2010-10-06

  The present invention relates to the use of combinations comprising pipamperone and an SSRI, SNDRI or SNRI and compositions comprising the same for the treatment of mood or anxiety disorders.

  本发明涉及由哌潘立酮和 SSRI、SNDRI 或 SNRI 组成的组合物以及由其组成的组合物在治疗情绪或焦虑症方面的用途。